Leukemia in Children: Causes, Diagnosis & Treatment Guide

Leukemia is the most common cancer in children, accounting for roughly 28% of all pediatric cancers. Each year, about 3,500 children in the United States are diagnosed. The good news: survival rates have improved dramatically over the past 50 years, with overall cure rates now exceeding 85% for the most common subtype. But getting there requires early recognition, accurate diagnosis, and the right therapeutic strategy.

This guide covers what actually causes leukemia in children, how doctors diagnose it, and the therapeutic strategies used to treat it — including newer approaches that are changing outcomes for even the hardest-to-treat cases.

What Is Pediatric Leukemia?

Leukemia is a cancer of the blood-forming cells in the bone marrow. In children, the marrow starts producing massive numbers of abnormal, immature white blood cells (called blasts) that crowd out healthy red blood cells, white blood cells, and platelets. The result: a child who bruises easily, gets sick constantly, and feels exhausted.

Two types dominate pediatric leukemia:

ALL is by far the most common and also the most curable. AML is less common but significantly harder to treat.

What Causes Leukemia in Children?

Parents almost always ask: “Did we do something wrong?” The short answer is no. In the vast majority of cases, childhood leukemia arises from random genetic mutations that occur during normal cell division — not from anything a parent did or didn’t do.

These same spontaneous mutations can affect different cell lineages, which is why a subtype such as T cell lymphoblastic leukemia follows its own diagnostic and treatment path rather than reflecting any parental cause.

That said, certain factors increase risk:

• Genetic syndromes: Children with Down syndrome have a 10- to 20-fold increased risk of leukemia. Other predisposing conditions include Li-Fraumeni syndrome, neurofibromatosis type 1, and ataxia-telangiectasia.
• Inherited bone marrow failure syndromes: Fanconi anemia, Shwachman-Diamond syndrome, and dyskeratosis congenita all elevate risk.
• Prior radiation or chemotherapy exposure: Children treated for a previous cancer have a higher risk of developing secondary leukemia, particularly AML.
• Sibling with leukemia: An identical twin of a child with ALL has roughly a 25% chance of also developing it if diagnosed before age 1.

The Molecular Picture

At the cellular level, leukemia develops when mutations disrupt normal blood cell development (hematopoiesis). Key genetic events include:

• Chromosomal translocations — such as the ETV6-RUNX1 fusion (found in ~25% of childhood ALL), which disrupts normal transcription factor function
• Hyperdiploidy — leukemic cells with more than 50 chromosomes, generally associated with a favorable prognosis
• Activating mutations in FLT3, NRAS, and KRAS oncogenes, particularly in AML
• Epigenetic changes — abnormal DNA methylation and histone modification that silence tumor suppressor genes

These mutations don’t happen because of diet, vaccines, or household chemicals. Research from large epidemiological studies has consistently failed to link common environmental exposures to childhood leukemia in any meaningful way.

Warning Signs Every Parent Should Know

The tricky part: early leukemia symptoms look like a dozen ordinary childhood illnesses. But when multiple symptoms cluster together or persist beyond what’s expected, that’s the red flag.

• Persistent fatigue and pallor (from anemia — hemoglobin often drops below 8 g/dL)
• Unexplained bruising or petechiae (platelet counts frequently below 50,000/µL)
• Recurrent fevers without a clear infection source
• Bone or joint pain — severe enough that a child may limp or refuse to walk
• Swollen lymph nodes, liver, or spleen
• Unexplained weight loss

Bone pain is particularly telling. A child who suddenly develops severe limb pain and has abnormal blood counts should be evaluated urgently for leukemia.

How Is Childhood Leukemia Diagnosed?

Diagnosis typically follows a specific sequence:

1. Complete Blood Count (CBC): This is usually the first clue. A child with leukemia may show a white blood cell count anywhere from extremely low (<2,000/µL) to extremely high (>100,000/µL), along with low hemoglobin and low platelets. Blasts on the peripheral blood smear raise immediate concern.

2. Bone Marrow Aspiration and Biopsy: The gold standard. A diagnosis of leukemia requires ≥20% blasts in the bone marrow (though most children present with 60–90% blasts). This procedure is done under sedation and typically takes 15–20 minutes.

3. Flow Cytometry and Immunophenotyping: Identifies the exact cell lineage (B-cell ALL vs. T-cell ALL vs. AML subtypes) by detecting surface markers like CD10, CD19, CD34, and MPO.

4. Cytogenetics and Molecular Testing: FISH, karyotyping, and next-generation sequencing identify specific chromosomal abnormalities and mutations that determine risk stratification and treatment intensity.

5. Lumbar Puncture: Performed at diagnosis to check for central nervous system (CNS) involvement, which is present in about 3–5% of ALL cases at diagnosis.

Therapeutic Strategies for Childhood Leukemia

Standard Chemotherapy

Treatment for ALL typically spans 2–3 years and follows a structured protocol with four phases: induction, consolidation, interim maintenance, and long-term maintenance. The goal of induction is to achieve complete remission — defined as less than 5% blasts in the marrow — which occurs in about 98% of children with ALL by day 29.

AML treatment is shorter (approximately 6 months) but far more intensive, often requiring prolonged hospitalization.

Risk-Adapted Therapy

Modern pediatric leukemia treatment is heavily risk-stratified. Children with favorable genetics (like ETV6-RUNX1 or hyperdiploidy) receive less intensive therapy, sparing them unnecessary toxicity. Those with high-risk features — such as MLL rearrangements, Philadelphia chromosome–positive ALL, or poor early treatment response — receive augmented regimens.

Targeted and Immunotherapy

This is where the field has made dramatic progress in recent years:

• Blinatumomab — a bispecific T-cell engager (BiTE) that bridges T cells to CD19-positive leukemia cells. Now used in first relapse and increasingly in frontline therapy for high-risk ALL.
• CAR-T cell therapy (tisagenlecleucel) — FDA-approved for relapsed/refractory B-cell ALL in patients up to age 25. Achieves complete remission in approximately 80% of patients who have failed other treatments.
• Inotuzumab ozogamicin — an antibody-drug conjugate targeting CD22, showing strong results in relapsed ALL.
• Tyrosine kinase inhibitors (imatinib, dasatinib) — standard of care for Philadelphia chromosome–positive ALL and CML.

Stem Cell Transplant

Hematopoietic stem cell transplant (HSCT) is reserved for children with very high-risk or relapsed disease. It carries significant risks — including graft-versus-host disease and infections — but remains potentially curative when other approaches fail.

When to See a Doctor

Take your child to a pediatrician promptly — and ask for a CBC — if you notice:

• Fatigue and pallor lasting more than 1–2 weeks without explanation
• Unexplained bruising, especially in unusual locations (trunk, face)
• Persistent or recurrent fevers
• Bone pain that wakes a child at night or limits activity
• Palpable lymph nodes that are enlarging or persist beyond 4 weeks

If a CBC shows abnormalities — particularly blasts on the smear, very low platelets, or an unexplained elevated WBC — your child should be referred to a pediatric hematologist-oncologist immediately. Same-day referral is appropriate when blasts are present.

Frequently Asked Questions

Is childhood leukemia hereditary?

In the vast majority of cases, no. Only about 5% of childhood leukemias are linked to a known inherited genetic syndrome. Most cases result from acquired (not inherited) mutations that arise spontaneously. Having one child with leukemia does not significantly increase the risk for siblings, except in the case of identical twins diagnosed in infancy.

What is the survival rate for childhood leukemia?

For ALL — the most common type — the 5-year overall survival rate now exceeds 90% in developed countries. AML survival has improved to approximately 65–70%. These numbers represent enormous progress; in the 1960s, childhood leukemia was almost universally fatal.

How long does treatment last?

ALL treatment typically lasts 2 years for girls and 2.5–3 years for boys (boys receive longer maintenance due to a higher relapse risk). AML treatment is more intensive but shorter, usually around 6 months of active chemotherapy.

Can childhood leukemia come back after treatment?

Yes. Relapse occurs in roughly 15–20% of ALL cases and 30–40% of AML cases. Most relapses happen within the first 2 years after completing treatment. Late relapses (occurring more than 3 years off therapy) generally carry a better prognosis than early relapses. Newer immunotherapies like CAR-T cells have dramatically improved outcomes for relapsed disease.

Are there long-term side effects of treatment?

Survivors of childhood leukemia can experience late effects including secondary cancers, heart problems (from anthracycline chemotherapy), bone density loss, neurocognitive changes, and fertility issues. Long-term survivorship follow-up — ideally at a dedicated survivorship clinic — is recommended for all childhood cancer survivors throughout their lives.

Related guides

• Understanding leukemia bruises on the spine in children causes diagnosis and treatment
• An overview of pediatric oncology understanding diagnosis and treatment
• Understanding the composition and function of bone marrow
• Understanding white vs red blood cells their role in health
• Understanding and diagnosing chronic myeloid leukemia
• A comprehensive guide to diagnosing leukemia
• Understanding pediatric acute lymphoblastic leukemia a comprehensive overview